Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010

This article was originally published in PharmAsia News

Executive Summary

Eisai announced April 11 it has abandoned development of its novel AMPA receptor antagonist perampanel in Parkinson's disease after a second Phase III trial failed, but the Tokyo firm is forging ahead with the compound in other neurological indications

You may also be interested in...



Eisai's Perampanel Shows Positive Phase III Results For Epilepsy Following Failure As Parkinson's Treatment

TOKYO - Positive Phase III results in epilepsy for the AMPA receptor antagonoist perampanel set it on a rebound following Eisai's decision two years ago to abandon development of the drug in Parkinson's disease

Eisai's Perampanel Shows Positive Phase III Results For Epilepsy Following Failure As Parkinson's Treatment

TOKYO - Positive Phase III results in epilepsy for the AMPA receptor antagonoist perampanel set it on a rebound following Eisai's decision two years ago to abandon development of the drug in Parkinson's disease

Eisai's Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson's Disease

Eisai has pushed back the filing of its novel AMPA receptor antagonist perampanel for Parkinson's disease from fiscal 2007 to fiscal fourth quarter 2008 (ended March 31, 2009) in the U.S. and Europe because the drug failed to show an efficacy benefit over placebo in a Phase III study, Eisai said Oct. 30

UsernamePublicRestriction

Register

LL1133229

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel